Developer of drugs and clinical products to address unmet clinical needs.
Developer of drugs and clinical products to address unmet clinical needs.
Drug Discovery📍 Shanghai, ChinaFounded 2017
Current Valuation
$588M
as of 2021-Q2
PRIVATE
QL Price
$588M
0% vs last round
QuantLogix's current estimate for Alpha Biopharma, published 2026-09-27 — in line with the last disclosed round of $588M (2021-Q2).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$588M
2021-Q2
weight 0.03
How this price has held up
No round has priced for Alpha Biopharma since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Alpha Biopharma, 2026-09-27 (2d3385622e30d230).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Alpha Biopharma going public?
No. Alpha Biopharma is private and has not filed to go public. There is no S-1 on file.
What is Alpha Biopharma's valuation in 2026?
Alpha Biopharma is valued at $588M as of 2021-Q2, set by its Series B ($25M, Apr 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Alpha Biopharma filed an S-1?
No public S-1 is on file for Alpha Biopharma.
How much has Alpha Biopharma raised?
Alpha Biopharma has raised $92M in total, most recently a Series B of $25M in Apr 2021.
Is Alpha Biopharma publicly traded — can you buy Alpha Biopharma stock?
No. Alpha Biopharma is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Alpha Biopharma on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
Shanghai, China
Employees
3
Total Raised
$92M
Last Round
Series B — $25M (Apr 2021)
IPO Status
private
Fundraising Status
Series B · $25M · 5y 5mo ago
privateTotal raised $92M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$25M
Apr 2021
—
$588M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Alpha Biopharma — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
7
via ashby
Product-build share
86%
engineering, research, product, design
Trajectory
steady
heavy product build — 86% of open roles are product-building functions (engineering/research/product) — 5 of 7 open roles are product.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
AI Product LeadAI Product ManagerSr. Product Manager (CN) Lead AI EngineerAI Product Manager (EU)Technical Product Manager (CN)
Counted from Alpha Biopharma's live job board as of 2026-09-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareBiopharmaTherapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q2. Refreshed quarterly.